Publications by authors named "Antoni Gilabert"
Article Synopsis
- Drug-related problems (DRPs) are significant but preventable issues patients face due to medication use or misuse, yet current prevention policies are inadequate.
- A clinical trial conducted with 769 adult patients visiting the emergency department for DRPs evaluated the effectiveness of a specialized prevention bundle versus standard care, focusing on readmission rates within 30 days.
- Results indicated that the intervention group had a lower readmission rate (7.3%) compared to the control group (10.4%), suggesting that the DRP prevention bundle could effectively reduce hospital readmissions.
Background: In 2011 the first payment-by-results (PbR) scheme in Catalonia was signed between the Catalan Institute of Oncology (ICO), the Catalan Health Service, and AstraZeneca (AZ) for the introduction of gefitinib in the treatment of advanced EGFR-mutation positive non-small-cell lung cancer. The PbR scheme includes two evaluation points: at week 8, responses, stabilization and progression were evaluated, and at week 16 stabilization was confirmed. AZ was to reimburse the total treatment cost of patients that failed treatment, defined as progression at weeks 8 or 16.
View Article and Find Full Text PDFBackground: Introduction of new drugs is a dynamic process with a high impact on consumption and expenditure.
Objective: To analyze the prescription of new drugs and the associated costs in public health care in Catalunya, Spain, in 2002. The analysis also attempts a perspective of consumption in relation to the grade of therapeutic innovation of the new drugs.